Olema Pharmaceuticals, Inc.
No SEC Form 4 filings for $OLMA in the last 30 days.
Swedbank AB disclosed a new position in Olema Pharmaceuticals (NASDAQ:OLMA), buying 55,100 shares for about $1.38 million in Q4, raising its stake to 0.08%. Other filings show Jennison Associates, Kingdon Capital, Ameriprise, Candriam and Vanguard also adjusted holdings. Olema reported Q1 EPS of -$0.52 on May 12.
Olema Pharmaceuticals director Raman Prakash has been granted 27,061 stock options as equity compensation, with an exercise price of $14.59 per share, expiring on April 27, 2036. The options vest based on continuous service, with one portion vesting in full on June 11, 2026, and another in 36 equal monthly installments starting April 28, 2026. This transaction reflects compensation rather than open-market purchases.
Olema Pharmaceuticals CEO Sean Bohen provided updates on the company's pipeline, including an expected Fall readout for the OPERA-01 trial of palazestrant and Q2 2026 data for the KAT6 inhibitor OP-3136. Bohen also addressed the departure of CFO/COO Shane Kovacs, framing it as the company prepares for potential commercialization of palazestrant in the U.S. and seeks ex-U.S. partners. He emphasized palazestrant's potential as a best-in-class oral SERD, citing its pharmacologic attributes and past clinical results.
